SCHEMBL6872203

SCHEMBL6872203

CO[C@H]1O[C@H](COCc2ccccc2)[C@@H](OCc2ccccc2)[C@H]1OCc1ccccc1

nearest known ligand 0.70

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SSTR1 P30872 1/20 0.70
SSTR2 P30874 1/20 0.70
SSTR4 P31391 1/20 0.70
SSTR3 P32745 1/20 0.70
SSTR5 P35346 1/20 0.70
NT5E P21589 1/20 0.55
GJB2 P29033 1/20 0.54
PTPN1 P18031 9/20 0.54
PTPN2 P17706 4/20 0.54
BCHE P06276 1/20 0.54
CDC25B P30305 6/20 0.51
HTR1A P08908 1/20 0.50
PTPN6 P29350 2/20 0.49
PTPN11 Q06124 2/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
CA9 Q16790 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31491488 1.00 SSTR1 (0.70) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL15338590 1.00 SSTR1 (0.70) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL1957129 1.00 SSTR1 (0.70) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL3752668 1.00 SSTR1 (0.70) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL13204994 1.00 SSTR1 (0.70) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL13591468 1.00 SSTR1 (0.70) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL12896361 1.00 SSTR1 (0.70) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL5961352 1.00 SSTR1 (0.70) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL3752664 1.00 SSTR1 (0.70) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL30928985 1.00 SSTR1 (0.70) SSTR1SSTR2SSTR4SSTR3SSTR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119930717-A 1-Triazole ribose derivative and preparation method and application thereof 上海泓博智源医药股份有限公司 2025-05-06 CN disclosed
US-20140066398-A1 HCV POLYMERASE INHIBITORS MEDIVIR, AB (SE) 2014-03-06 US disclosed
WO-2013084165-A1 HCV POLYMERASE INHIBITORS MEDIVIR AB (SE) 2013-06-13 WO disclosed
US-20130143835-A1 HCV Polymerase Inhibitors MEDIVIR AB (SE) 2013-06-06 US disclosed
EP-0832091-B1 C-4' MODIFIED ADENOSINE KINASE INHIBITORS GENSIA SICOR INC (US) 2004-01-14 EP disclosed
US-5763596-A PYROLO PYRIMIDINE AND PYRAZOLO PYRIMIDINE COMPOUMDS; TREATMENT OF CARDIOVASCULAR AND BRAIN DISORDERS, ANTIINFLAMMATORY AGENTS METABASIS THERAPEUTICS, INC. (US) 1998-06-09 US disclosed
US-5674998-A FOR TREATING CARDIOVASCULAR OR BRAIN DISORDERS, OR AS ANTIINFLAMMATORY AGENT GENSIA INC. (US) 1997-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130143835-A1 HCV Polymerase Inhibitors POLI, HAVCR2, EIF2AK2 SSTR1 4414/4885SSTR2 4197/4885SSTR4 4286/4885
US-20140066398-A1 HCV POLYMERASE INHIBITORS POLI, HAVCR2, EIF2AK2 SSTR1 4414/4885SSTR2 4197/4885SSTR4 4286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.